Position in SYRE
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$26,916,320
New position
Shares Held
303,180
first reported quarter
Ownership
0.344%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#48
of 266 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 59%
Shared 0%
None 41%
Position in Biotechnology
Healthcare · as of Jun 30, 2026JENNISON ASSOCIATES LLC holds $3,808,452,552 across 46 Biotechnology names. SYRE ranks #26 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,998,530 | $1,489,459,806 | |
| 2 | ARGX |
Argenx SE
|
226,200 | $209,861,574 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
4,481,964 | $158,616,705 | |
| 4 | PVLA |
Palvella Therapeutics, Inc.
|
960,619 | $146,801,794 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
1,151,681 | $141,173,056 | |
| 6 | SRRK |
Scholar Rock Holding Corp
|
2,358,587 | $129,722,285 | |
| 7 | IMVT |
Immunovant, Inc.
|
3,310,238 | $127,543,470 | |
| 8 | ARQT |
Arcutis Biotherapeutics, Inc.
|
4,219,058 | $110,623,700 |
All Filings in SYRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $26,916,320 | 303,180 | Shares | Defined | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||